The post XRP Technical Analysis Jan 23 appeared on BitcoinEthereumNews.com. XRP market structure maintains the downtrend; recent LH/LL patterns are dominant, butThe post XRP Technical Analysis Jan 23 appeared on BitcoinEthereumNews.com. XRP market structure maintains the downtrend; recent LH/LL patterns are dominant, but

XRP Technical Analysis Jan 23

XRP market structure maintains the downtrend; recent LH/LL patterns are dominant, but BOS above $1.9686 could signal upside.

Market Structure Overview

XRP is trading at $1.91 as of January 23, 2026, and stayed in the $1.90-$1.96 range with a -1.90% drop over the last 24 hours. The market structure generally shows a downtrend; lower highs (LH) and lower lows (LL) patterns are clearly observed. This indicates that the price has consistently broken below recent swing highs ($1.9686, $1.9165) and lows ($1.8783). Remaining below the short-term EMA20 ($2.01) confirms the bearish short-term structure. The Supertrend signal is bearish, and the $2.20 resistance level is strong. RSI at 41.34 is in the neutral-bearish zone, with MACD’s negative histogram supporting downside momentum. Multi-timeframe (MTF) analysis shows a total of 11 strong levels across 1D, 3D, and 1W timeframes: 2 supports/3 resistances on 1D, 2S/2R on 3D, and a balanced 3S/3R on 1W. News flow is calm, with structural movements remaining technically driven. Check the links for XRP Spot Analysis and XRP Futures Analysis.

Trend Analysis: Uptrend or Downtrend?

Uptrend Signals

For an uptrend, higher highs (HH) and higher lows (HL) patterns are sought; the price needs to break above previous swing lows and form new highs. Currently, XRP shows weak HL signals: the $1.8783 support has held strong so far (score 78/100), but breaking $1.9686 resistance (score 71) is critical for the first BOS (break of structure). A close above EMA20 and RSI crossing above 50 could support a bullish shift. Structural target at $2.5023 (score 45), but it remains distant under current LH/LL dominance. Breaking above $2.0227 resistance (score 65) would signal a trend change (CHoCH – change of character).

Downtrend Risk

The downtrend is confirmed by LH/LL: Rejection from the recent swing high at $1.9686, followed by $1.9165 LH formation and approach to $1.8783 LL. This pattern indicates the trend remains intact; bearish bias persists as long as price stays below EMA20. MACD is negative and RSI at 41 is nearing oversold, but momentum remains downward. A break below $1.8783 (bearish BOS) opens the path to $1.7711 (score 68) and structural target at $1.3876 (score 22). LL patterns on the 1W timeframe strongly support this.

Structure Break (BOS) Levels

BOS levels confirm trend changes. Bullish BOS: Daily close above $1.9686 (main swing high), followed by a move to $2.0227. This breaks the LH pattern and signals a shift to HL; CHoCH forms. Bearish BOS: Break below $1.8783 confirms LL, targeting $1.7711 and $1.3876. In MTF, 1D resistances (3) increase bearish pressure, while 1W supports (3) heighten deep downside risk. Exceeding these levels invalidates the trend: Upside BOS negates the downtrend, downside BOS negates the uptrend. Watch: Micro support around $1.90, acceleration on break.

Swing Points and Their Importance

Recent Swing Highs

Recent swing highs: $1.9686 (score 71/100, main resistance), $1.9165 (65/100, LH level), $2.0227 (65/100, near EMA20). These points are rejection zones; bounces from here strengthen the LH pattern. $1.9686 represents the short-term trendline – a break opens the door to HH, while staying below reinforces LL. Importance: High-score swings (70+) are liquidity collection points.

Recent Swing Lows

Recent swing lows: $1.8783 (score 78/100, critical support), $1.7711 (68/100, secondary). These levels should be tested for HL; holding creates bullish divergence. A break increases bearish momentum. Importance: Swing lows are trend reversal pivots – high scores indicate institutional interest. $1.8783 is the main HTF support on 1D MTF.

Bitcoin Correlation

BTC is flat at $89,883 with +0.01%, but in a downtrend with bearish Supertrend. BTC supports at $89,160 / $86,739 / $84,681; resistances at $90,245 / $92,308. BTC.Dominance is not rising but bearish Supertrend signals caution for altcoins. XRP has 0.8% correlation to BTC; BTC below $89k tests XRP’s $1.8783. BTC BOS above $90k could trigger XRP rally to $1.9686. BTC downtrend continuation deepens XRP’s LH/LL – watch BTC moves without alts.

Structural Outlook and Expectations

Structural outlook is bearish: LH/LL dominant, consolidation below EMA. Trend intact; BOS above $1.9686 brings bullish shift, below $1.8783 brings bearish continuation. Educational note: Market structure is determined by HH/HL (bull) vs LH/LL (bear) – changes via BOS/CHoCH. Short-term $1.90-$1.96 range, breaks determine direction. Long-term, balanced 1W levels carry reversal potential. Risk management: Place stop-loss at swing levels. Market structures are dynamic; regular MTF checks essential.

This analysis uses the market views and methodology of Chief Analyst Devrim Cacal.

Senior Technical Analyst: James Mitchell

6 years of crypto market analysis

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/xrp-market-structure-january-23-2026-trend-analysis

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26